← FDA DRUG APPROVALS

FDA NDA · NDA010093

BIPHETAMINE 7.5

Sponsor: UCB INC

APPLICATION
NDA010093
TYPE
NDA
ORIGINAL APPROVAL
1955-09-09
LATEST ACTION
1983-06-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

BIPHETAMINE 7.5Discontinued
AMPHETAMINE RESIN COMPLEX EQ 3.75MG BASE, DEXTROAMPHETAMINE RESIN COMPLEX EQ 3.75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
BIPHETAMINE 12.5Discontinued
AMPHETAMINE RESIN COMPLEX EQ 6.25MG BASE, DEXTROAMPHETAMINE RESIN COMPLEX EQ 6.25MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
BIPHETAMINE 20Discontinued
AMPHETAMINE RESIN COMPLEX EQ 10MG BASE, DEXTROAMPHETAMINE RESIN COMPLEX EQ 10MG BASE · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

1983-06-16Manufacturing (CMC) · Supplement 13 · standardAP
1983-05-06Manufacturing (CMC) · Supplement 12 · standardAP
1979-04-04Labeling · Supplement 11 · standardAP
1955-09-09Type 2 - New Active Ingredient · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →